Imexpharm

Imexpharm EBIT CAGR 5Y

The EBIT CAGR (5 Year) of Imexpharm (IMP.VN) as of Oct 27, 2026 is 11.99 %. In the previous year, EBIT CAGR (5 Year) was 11.99 % — a change of 0.00% (lower).

EBIT CAGR 5Y

11.99 %

YoY

0.00%

Last updated:

EBIT CAGR (5 Year) of Imexpharm is 2025 11.99 % . EBIT CAGR (5 Year) of Imexpharm was 2024 11.99 % . It decreases by 0.00% lower compared to the previous year.

The Imexpharm EBIT CAGR 5Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT CAGR 5Y
Date
EBIT CAGR 5Y
Jan 1, 2018
11.99 VND
Jan 1, 2019
11.99 VND
Jan 1, 2020
11.99 VND
Jan 1, 2021
11.99 VND
Jan 1, 2022
11.99 VND
Jan 1, 2023
11.99 VND
Jan 1, 2024
11.99 VND
Jan 1, 2025
11.99 VND
The Imexpharm EBIT CAGR 5Y history
YEAREBIT CAGR 5YYoY
11.99 %0.00%
11.99 %0.00%
11.99 %0.00%
11.99 %0.00%
11.99 %0.00%
11.99 %0.00%
11.99 %0.00%
11.99 %0.00%
11.99 %0.00%
11.99 %0.00%
11.99 %0.00%
11.99 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imexpharm Stock analysis

What does Imexpharm do? Imexpharm Corp manufactures and trades pharmaceuticals, medicinal chemicals, and botanical products, including antiseptics, traditional medicine, medical equipment, cosmetics, and supplemental food and drinks. The company provides packaging and warehousing services specifically for pharmaceutical storage. It also cultivates medicinal herbs. Imexpharm Corp serves the pharmaceutical industry and healthcare sector through its manufacturing, import, export, and trade operations, targeting businesses requiring medicinal products and services. The company's revenue streams include the sale of manufactured pharmaceuticals, imported and exported goods, and services such as packaging and warehousing. Its customers are businesses in the healthcare sector, including distributors and retailers of pharmaceuticals, medical equipment, and related products. The firm's operations span manufacturing, import, export, and trade, with additional services supporting the pharmaceutical supply chain. Imexpharm Corp's product portfolio covers a wide range of medicinal and health-related items, from antiseptics to supplemental food and drinks. The company's involvement in medicinal herb cultivation supports its production of traditional medicine and herbal-based products. This vertical integration enhances its ability to supply comprehensive solutions to healthcare businesses. Imexpharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imexpharm stock

EBIT CAGR (5 Year) of Imexpharm is 11.99 % in 2025.

On Eulerpool you can find the complete historical development of EBIT CAGR (5 Year) Imexpharm since 2006 – with annual values, charts, and detailed analysis.

The 5-year EBIT CAGR shows the compound annual growth rate of EBIT over the past five years.

To evaluate EBIT CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT CAGR (5 Year).

EBIT CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT CAGR (5 Year)'s Imexpharm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Imexpharm

All Key Metrics — Imexpharm